Core-Vector Core

核心向量核心

• 批准号: 7568964
• 负责人: JAKOB REISER
• 金额: $ 21.17万
• 依托单位: LSU HEALTH SCIENCES CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7568964
• 关键词: Adenoviruses; Animals; Antigens; CXCR3 gene; Fowlpox virus; Host Defense; Immunoglobulin G; Infection; Interleukin-15; Interleukin-17; Ligands; Louisiana; Lung; Ovalbumin; Pneumocystis; Program Research Project Grants; Recombinants; Research; Research Activity; Research Personnel; Research Project Grants; Role; Scientist; Support of Research; Testing; Viral Vector; base; mycobacterial; vector

The Vector Core will provide viral vectors to investigators for each research project in the context of this Program Project Grant. The Vector Core will construct, produce and test adenovirus-based vectors. These vectors will be used to express CXCR3 ligands, IL-17, IL-17R-IgG, mycobacterial and Pneumocystis antigens, and ovalbumin (OVA) in the lungs of experimental animals outlined in Projects 1, 2 and 4. The Vector Core will also construct, produce and test recombinant fowlpox viruses (FPV) expressing mycobacterial antigens, CXCR3 ligands and OVA. Recombinant FPV vectors will be used in prime-boost approaches outlined in Projects 1 to 4.

载体核心将为本计划项目拨款范围内的每个研究项目的研究人员提供病毒载体。 Vector Core 将构建、生产和测试基于腺病毒的载体。这些载体将用于在项目 1、2 和 4 中概述的实验动物的肺部表达 CXCR3 配体、IL-17、IL-17R-IgG、分枝杆菌和肺孢子菌抗原以及卵清蛋白 (OVA)。构建、生产和测试表达分枝杆菌抗原、CXCR3 配体和 OVA 的重组鸡痘病毒 (FPV)。重组 FPV 载体将用于项目 1 至 4 中概述的初免-加强方法。